专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09447470B2 Tumor grading and cancer prognosis 有权
标题翻译：肿瘤分级和癌症预后
公开(公告)号：US09447470B2
公开(公告)日：2016-09-20
申请号：US12718973
申请日：2010-03-06
申请人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
发明人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112
摘要： The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
摘要翻译：该公开内容包括鉴定和使用与癌症具有临床相关性的基因表达谱或模式。特别地，本公开包括与肿瘤等级相关表达的基因的身份。公开了基因表达水平作为确定患者肿瘤分级的分子指标，并预测了患者的临床结果以及预后。癌症的分子分级可以任选地与用于诊断癌症及其预后的第二分子指数组合使用。本公开还包括用于预测癌症复发和/或预测转移性癌症发生的方法。为了诊断或预后，本公开还包括基于预期寿命，癌症复发和/或癌症转移的可能性来确定或选择癌症治疗的方法。

2. 发明申请

US20110136680A1 TUMOR GRADING AND CANCER PROGNOSIS 有权
标题翻译：肿瘤分级和癌症预后
公开(公告)号：US20110136680A1
公开(公告)日：2011-06-09
申请号：US12718973
申请日：2010-03-06
申请人： Mark G. Erlander , Xiao-Jun Ma , Dennis Sgroi
发明人： Mark G. Erlander , Xiao-Jun Ma , Dennis Sgroi
IPC分类号： C12Q1/68 , C40B30/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112
摘要： The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
摘要翻译：该公开内容包括鉴定和使用与癌症具有临床相关性的基因表达谱或模式。特别地，本公开包括与肿瘤等级相关表达的基因的身份。公开了基因表达水平作为确定患者肿瘤分级的分子指标，并预测了患者的临床结果以及预后。癌症的分子分级可以任选地与用于诊断癌症及其预后的第二分子指数组合使用。本公开还包括用于预测癌症复发和/或预测转移性癌症发生的方法。为了诊断或预后，本公开还包括基于预期寿命，癌症复发和/或癌症转移的可能性来确定或选择癌症治疗的方法。

3. 发明申请

US20090270271A1 3' Biased Detection of Nucleic Acids 审中-公开
标题翻译： 3'核酸的偏置检测
公开(公告)号：US20090270271A1
公开(公告)日：2009-10-29
申请号：US12210807
申请日：2008-09-15
申请人： Mark G. Erlander , Xiao-Jun Ma , Thomas Baer
发明人： Mark G. Erlander , Xiao-Jun Ma , Thomas Baer
IPC分类号： C40B30/04
CPC分类号： C12Q1/6876 , C12Q1/6809 , C12Q1/6851 , C12Q1/686 , C12Q2565/501
摘要： The invention provides materials and methods for the detection of nucleic acid expression via the 3′ portion of expressed sequences. Embodiments of the invention include the use of microarrays comprising nucleic acid probes that are complementary to the 3′ end of expressed sequences and by the use of quantitative PCR (Q-PCR) based amplification of sequences found at or near the 3′ end of expressed sequences. The invention may be used to detect the presence of expressed nucleic acids encoding particular gene products (sequences present in a “transcriptome”).
摘要翻译：本发明提供了通过表达序列的3'部分检测核酸表达的材料和方法。本发明的实施方案包括使用包含与表达的序列的3'末端互补的核酸探针的微阵列，以及通过使用基于定量PCR（Q-PCR）的扩增在3'末端发现的序列的表达序列。本发明可用于检测编码特定基因产物（“转录组”中存在的序列）的表达的核酸的存在。

4. 发明申请

US20090215037A1 Dynamically expressed genes with reduced redundancy 审中-公开
标题翻译：动态表达减少冗余的基因
公开(公告)号：US20090215037A1
公开(公告)日：2009-08-27
申请号：US11816623
申请日：2006-02-16
申请人： Xiao-Jun Ma , Xianqun Wang , Mark G. Erlander
发明人： Xiao-Jun Ma , Xianqun Wang , Mark G. Erlander
IPC分类号： C12Q1/68 , C40B40/06
CPC分类号： G16B25/00 , C12Q1/6837 , C12Q1/6886 , G16B40/00
摘要： This invention relates to the identification and use of a subset of transcribed genes, wherein the expression of genes in the subset are able to classify cells among a plurality of classes. Methods for the identification or selection of such subsets are provided, along with computer implemented means for the application of the methods. The invention further provides physical embodiments based on the gene sequences of the subsets as well as methods for the use of the identified sets of gene sequences to classify a cell or tissue sample.
摘要翻译：本发明涉及鉴定和使用转录基因子集，其中该子集中基因的表达能够对多个类别之间的细胞进行分类。提供了用于识别或选择这些子集的方法，以及用于应用方法的计算机实现的方法。本发明还提供了基于子集的基因序列的物理实施方案以及使用所鉴定的基因序列集合来分类细胞或组织样品的方法。

5. 发明授权

US07504214B2 Predicting outcome with tamoxifen in breast cancer 失效
标题翻译：乳腺癌中他莫昔芬的预测结果
公开(公告)号：US07504214B2
公开(公告)日：2009-03-17
申请号：US10727100
申请日：2003-12-02
申请人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
发明人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
IPC分类号： C12Q1/68 , C07H21/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154 , C12Q2600/158
摘要： Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
摘要翻译：提供方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与他莫昔芬治疗的反应性或缺乏相关。基于来自乳腺癌独立病例的参考乳腺组织样本的抽样来鉴定特征谱，并提供可靠的一组分子标准，用于预测使用他莫昔芬治疗患有ER +乳腺癌的受试者的功效。提供了另外的方法和组合物，用于通过使用三种生物标志物来预测ER +乳腺癌患者中的他莫昔芬反应性。两种生物标志物显示与他莫昔芬反应相关的增加的表达，而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。

6. 发明授权

US06548270B1 DNA encoding human acid-sensing ion channel BNaC4 (ASIC4) 有权
标题翻译：编码人酸感应离子通道BNaC4（ASIC4）的DNA
公开(公告)号：US06548270B1
公开(公告)日：2003-04-15
申请号：US09518959
申请日：2000-03-03
申请人： Adrienne Elizabeth Dubin , Jayashree Pyati , Rene Huvar , Mark G. Erlander
发明人： Adrienne Elizabeth Dubin , Jayashree Pyati , Rene Huvar , Mark G. Erlander
IPC分类号： C12N1512
CPC分类号： C07K14/705 , A61K38/00
摘要： DNA encoding human acid sensing ion channel BnaC4 has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
摘要翻译：已经克隆并表征编码人感应离子通道BnaC4的DNA。重组蛋白能够形成生物活性蛋白。 cDNA已经在产生活性重组蛋白的重组宿主细胞中表达。重组蛋白也从重组宿主细胞中纯化。此外，重组宿主细胞用于建立识别受体活性调节剂的方法，并鉴定受体调节剂。

7. 发明授权

US5968817A DNA encoding serotonin receptors 失效
标题翻译：编码血清素受体的DNA
公开(公告)号：US5968817A
公开(公告)日：1999-10-19
申请号：US31538
申请日：1993-03-15
申请人： J. Gregor Sutcliffe , Mark G. Erlander , Timothy W. Lovenberg
发明人： J. Gregor Sutcliffe , Mark G. Erlander , Timothy W. Lovenberg
IPC分类号： C07K14/705 , C12N15/12
CPC分类号： C07K14/70571
摘要： The present invention describes nucleic acid molecules encoding human serotonin receptors, recombinant serotonin receptor proteins, cultured cells expressing recombinant serotonin receptor proteins, antibodies immunoreactive with serotonin receptor proteins, polypeptide serotonin receptor antagonists, oligonucleotide probes used for detecting nucleic acids which encode a human serotonin receptor, and nonhuman transgenic animals which express recombinant human serotonin receptor. Also disclosed are methods for screening for ligand binding to the described serotonin receptors and for serotonin receptor agonists and antagonists, for detection of serotonin receptors in tissues, and for therapeutic treatments involving the described human serotonin receptors.
摘要翻译：本发明描述了编码人5-羟色胺受体的核酸分子，重组5-羟色胺受体蛋白，表达重组5-羟色胺受体蛋白的培养细胞，与5-羟色胺受体蛋白免疫反应的抗体，多肽血清素受体拮抗剂，用于检测编码人血清素受体的核酸的寡核苷酸探针，以及表达重组人血清素受体的非人类转基因动物。还公开了筛选与所述5-羟色胺受体和5-羟色胺受体激动剂和拮抗剂结合的配体，用于检测组织中的5-羟色胺受体以及涉及所述人血清素受体的治疗性治疗的方法。

8. 发明授权

US5846740A Methods and kits useful for detecting autoantibody to glutamic acid decarboxylase 失效
标题翻译：用于检测谷氨酸脱羧酶自身抗体的方法和试剂盒
公开(公告)号：US5846740A
公开(公告)日：1998-12-08
申请号：US484530
申请日：1995-09-22
申请人： Allan J. Tobin , Mark G. Erlander , Daniel L. Kaufman
发明人： Allan J. Tobin , Mark G. Erlander , Daniel L. Kaufman
IPC分类号： G01N33/564 , A61K38/00 , A61K39/00 , A61K39/395 , A61K49/00 , A61P37/00 , A61P37/06 , C07H21/04 , C07K16/40 , C12N1/21 , C12N5/10 , C12N5/20 , C12N9/88 , C12N15/09 , C12N15/60 , C12P21/08 , G01N33/573 , C07K1/00 , G01N33/53
CPC分类号： A61K38/51 , C07K16/40 , C12N9/88 , C12Y401/01015 , G01N33/564 , G01N33/573 , A61K38/00 , A61K39/00 , G01N2800/042 , G01N2800/24 , Y10S435/975
摘要： Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
摘要翻译：公开了可用于改善GAD相关自身免疫疾病的分离的多肽以及使用肽的诊断和治疗方法。

9. 发明授权

US09856533B2 Predicting breast cancer treatment outcome 有权
公开(公告)号：US09856533B2
公开(公告)日：2018-01-02
申请号：US10773761
申请日：2004-02-06
申请人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
发明人： Mark G. Erlander , Xiao-Jun Ma , Dennis C. Sgroi
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158
摘要： Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

10. 发明授权

US08926966B1 Cloned glutamic acid decarboxylase 失效
标题翻译：克隆谷氨酸脱羧酶
公开(公告)号：US08926966B1
公开(公告)日：2015-01-06
申请号：US08485725
申请日：1995-06-07
申请人： Allan J. Tobin , Mark G. Erlander , Daniel L. Kaufman
发明人： Allan J. Tobin , Mark G. Erlander , Daniel L. Kaufman
IPC分类号： A61K38/51
CPC分类号： A61K38/51 , A61K38/00 , A61K39/00 , C07K16/40 , C12N9/88 , C12Y401/01015 , G01N33/564 , G01N33/573 , G01N2800/042 , G01N2800/24 , Y10S435/975
摘要： Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
摘要翻译：公开了可用于改善GAD相关自身免疫疾病的分离的多肽以及使用肽的诊断和治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式